Quadrant Capital Group’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.15M | Buy |
2,052
+6
| +0.3% | +$3.85K | 0.03% | 504 |
|
|
2025
Q4 | $1.38M | Buy |
2,046
+20
| +1% | +$13.6K | 0.04% | 399 |
|
|
2025
Q3 | $1.29M | Buy |
2,026
+2
| +0.1% | +$1.21K | 0.04% | 392 |
|
|
2025
Q2 | $1.09M | Sell |
2,024
-173
| -8% | -$82.7K | 0.04% | 432 |
|
|
2025
Q1 | $923K | Buy |
2,197
+1,142
| +108% | +$496K | 0.03% | 416 |
|
|
2024
Q4 | $436K | Sell |
1,055
-79
| -7% | -$34.7K | 0.03% | 377 |
|
|
2024
Q3 | $573K | Sell |
1,134
-32
| -3% | -$15.5K | 0.04% | 307 |
|
|
2024
Q2 | $568K | Buy |
1,166
+71
| +6% | +$35.6K | 0.04% | 293 |
|
|
2024
Q1 | $591K | Buy |
1,095
+433
| +65% | +$237K | 0.05% | 286 |
|
|
2023
Q4 | $367K | Buy |
662
+84
| +15% | +$39.4K | 0.03% | 378 |
|
|
2023
Q3 | $253K | Sell |
578
-53
| -8% | -$26.4K | 0.03% | 437 |
|
|
2023
Q2 | $317K | Sell |
631
-74
| -10% | -$35.5K | 0.03% | 377 |
|
|
2023
Q1 | $353K | Buy |
705
+85
| +14% | +$40.7K | 0.04% | 347 |
|
|
2022
Q4 | $253K | Buy |
620
+53
| +9% | +$20.6K | 0.03% | 415 |
|
|
2022
Q3 | $185K | Buy |
567
+138
| +32% | +$50.7K | 0.02% | 456 |
|
|
2022
Q2 | $150K | Sell |
429
-18
| -4% | -$7.34K | 0.02% | 506 |
|
|
2022
Q1 | $244K | Buy |
447
+40
| +10% | +$21K | 0.03% | 395 |
|
|
2021
Q4 | $268K | Buy |
407
+14
| +4% | +$8.79K | 0.03% | 362 |
|
|
2021
Q3 | $244K | Buy |
393
+10
| +3% | +$6.72K | 0.03% | 340 |
|
|
2021
Q2 | $242K | Buy |
383
+20
| +6% | +$11K | 0.04% | 330 |
|
|
2021
Q1 | $178K | Buy |
363
+45
| +14% | +$22.5K | 0.03% | 383 |
|
|
2020
Q4 | $159K | Buy |
318
+14
| +5% | +$6.26K | 0.03% | 361 |
|
|
2020
Q3 | $120K | Buy |
304
+78
| +35% | +$28.8K | 0.03% | 374 |
|
|
2020
Q2 | $75K | Sell |
226
-721
| -76% | -$209K | 0.02% | 563 |
|
|
2020
Q1 | $228K | Buy |
947
+297
| +46% | +$77.5K | 0.04% | 357 |
|
|
2019
Q4 | $161K | Buy |
650
+138
| +27% | +$36.4K | 0.02% | 744 |
|
|
2019
Q3 | $135K | Buy |
512
+12
| +2% | +$3.34K | 0.02% | 741 |
|
|
2019
Q2 | $134K | Buy |
500
+446
| +826% | +$110K | 0.02% | 725 |
|
|
2019
Q1 | $10K | Sell |
54
-15
| -22% | -$3.1K | ﹤0.01% | 1697 |
|
|
2018
Q4 | $11K | Sell |
69
-3
| -4% | -$615 | ﹤0.01% | 1360 |
|
|
2018
Q3 | $16K | Hold |
72
| – | – | ﹤0.01% | 1082 |
|
|
2018
Q2 | $14K | Hold |
72
| – | – | ﹤0.01% | 1119 |
|
|
2018
Q1 | $11K | Buy |
72
+3
| +4% | +$554 | ﹤0.01% | 1218 |
|
|
2017
Q4 | $9K | Hold |
69
| – | – | ﹤0.01% | 1220 |
|
|
2017
Q3 | $9K | Hold |
69
| – | – | ﹤0.01% | 1220 |
|
|
2017
Q2 | $6K | Hold |
69
| – | – | ﹤0.01% | 1280 |
|
|
2017
Q1 | $9K | Buy |
69
+5
| +8% | +$689 | ﹤0.01% | 1114 |
|
|
2016
Q4 | $7K | Hold |
64
| – | – | ﹤0.01% | 1136 |
|
|
2016
Q3 | $6K | Hold |
64
| – | – | ﹤0.01% | 1208 |
|
|
2016
Q2 | $5K | Buy |
64
+26
| +68% | +$2.23K | ﹤0.01% | 1226 |
|
|
2016
Q1 | $2K | Hold |
38
| – | – | ﹤0.01% | 1359 |
|
|
2015
Q4 | $2K | Hold |
38
| – | – | ﹤0.01% | 1340 |
|
|
2015
Q3 | $2K | Sell |
38
-52
| -58% | -$3.73K | ﹤0.01% | 959 |
|
|
2015
Q2 | $5K | Buy |
+90
| New | +$6.23K | ﹤0.01% | 837 |
|
Other funds holding IDXX
VCM
VPM
Quadrant Capital Group's IDXX Position: Q1 2026 in Review
Quadrant Capital Group increased its Idexx Laboratories (IDXX) stake by 0.29% in Q1 2026, buying an estimated $3.85K and bringing the position to 2,052 shares worth $1.15M. The position accounts for 0.03% of the portfolio, ranked #504.
Quadrant Capital Group first reported a position in IDXX in Q2 2015 and has held it in 44 quarters since. The position peaked at $1.38M in Q4 2025. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.
- Quadrant Capital Group held 2,052 shares of Idexx Laboratories worth $1.15M as of Q1 2026.
- Quadrant Capital Group bought 6 Idexx Laboratories shares in Q1 2026, an estimated $3.85K.
- Idexx Laboratories made up 0.03% of Quadrant Capital Group's portfolio in Q1 2026, its #504 holding.
- Quadrant Capital Group first reported a position in Idexx Laboratories in Q2 2015 and has held it in 44 quarters since.
- Quadrant Capital Group's Idexx Laboratories position peaked at $1.38M in Q4 2025.
- 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.
Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.